DURATA THERAPEUTICS
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners. Durata is focused on Vicuron’s antibiotic drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.
DURATA THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2009-01-01
Address:
Branford, Connecticut, United States
Country:
United States
Website Url:
http://www.duratatherapeutics.com
Total Employee:
51+
Status:
Closed
Contact:
312-219-7000
Email Addresses:
[email protected]
Total Funding:
70 M USD
Technology used in webpage:
SPF Amazon Microsoft Azure DNS Amazon Virginia Region ASP.NET Ajax Amazon Sydney Region Cisco Ironport Cloud MarkMonitor DNS Xand
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-12-21 | Vicuron Pharmaceuticals | Vicuron Pharmaceuticals acquired by Durata Therapeutics | N/A |
Investors List
PDL Biopharma
PDL Biopharma investment in Post-IPO Equity - Durata Therapeutics
Official Site Inspections
http://www.duratatherapeutics.com
Unable to get host informations!!!
